



# 6° Congreso Argentino de Pediatría General Ambulatoria

19, 20 y 21 de noviembre de 2014

Sede: Sheraton Buenos Aires Hotel & Convention Center  
Ciudad de Buenos Aires



- Future II, Study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
- Hillman RJ, Giuliano AR, Palefsky JM et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012; 19: 261-7.
- Kohli M, Lawrence D, Haig J et al. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health. 2012; 12:872
- Wheeler CM, Castellsagué X, Gardland SM et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomized, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-110.
- WHO. Globocan. Lyon, France: World Health Organization; 2008 (Acceso Junio 2011).